FP
ABBV icon

Financial Perspectives’s AbbVie ABBV Stock Holding History

Financial Perspectives’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.87M Buy
13,217
+3
+0% +$665 0.8% 25
2025
Q4 		$3.02M Sell
13,214
-16
-0.1% -$3.65K 0.81% 25
2025
Q3 		$3.06M Buy
13,230
+92
+0.7% +$18.7K 0.85% 26
2025
Q2 		$2.44M Buy
13,138
+3
+0% +$558 0.74% 28
2025
Q1 		$2.75M Buy
13,135
+3
+0% +$583 0.94% 24
2024
Q4 		$2.33M Buy
13,132
+925
+8% +$170K 0.78% 26
2024
Q3 		$2.41M Buy
12,207
+3
+0% +$560 0.84% 25
2024
Q2 		$2.09M Buy
12,204
+3
+0% +$497 0.77% 26
2024
Q1 		$2.22M Sell
12,201
-5
-0% -$862 0.84% 24
2023
Q4 		$1.89M Sell
12,206
-21
-0.2% -$3.06K 0.77% 27
2023
Q3 		$1.82M Buy
12,227
+111
+0.9% +$16.3K 0.83% 26
2023
Q2 		$1.63M Buy
12,116
+19
+0.2% +$2.79K 0.72% 29
2023
Q1 		$1.93M Sell
12,097
-183
-1% -$28K 0.92% 23
2022
Q4 		$1.98M Buy
12,280
+2
+0% +$307 1.02% 21
2022
Q3 		$1.65M Buy
12,278
+129
+1% +$18.5K 0.92% 23
2022
Q2 		$1.86M Sell
12,149
-159
-1% -$24.3K 1.05% 21
2022
Q1 		$2M Buy
12,308
+275
+2% +$39.9K 0.93% 21
2021
Q4 		$1.63M Hold
12,033
– – 0.77% 23
2021
Q3 		$1.3M Buy
12,033
+93
+0.8% +$10.6K 0.65% 29
2021
Q2 		$1.34M Sell
11,940
-1,280,207
-99% -$144M 0.65% 30
2021
Q1 		$11.9M Buy
1,292,147
+1,281,674
+12,238% +$137M 0.59% 27
2020
Q4 		$1.12M Buy
10,473
+408
+4% +$39.2K 0.64% 28
2020
Q3 		$882K Buy
10,065
+1
+0% +$94 0.58% 28
2020
Q2 		$988K Buy
10,064
+38
+0.4% +$3.35K 0.71% 24
2020
Q1 		$764K Buy
10,026
+49
+0.5% +$4.17K 0.62% 26
2019
Q4 		$883K Buy
+9,977
New +$828K 0.6% 18

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Financial Perspectives's ABBV Position: Q1 2026 in Review

Financial Perspectives increased its AbbVie (ABBV) stake by 0.02% in Q1 2026, buying an estimated $665 and bringing the position to 13,217 shares worth $2.87M. The position accounts for 0.8% of the portfolio, ranked #25.

Financial Perspectives first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $11.9M in Q1 2021. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Financial Perspectives held 13,217 shares of AbbVie worth $2.87M as of Q1 2026.
  • Financial Perspectives bought 3 AbbVie shares in Q1 2026, an estimated $665.
  • AbbVie made up 0.8% of Financial Perspectives's portfolio in Q1 2026, its #25 holding.
  • Financial Perspectives first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • Financial Perspectives's AbbVie position peaked at $11.9M in Q1 2021.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Financial Perspectives's 13F filing for Q1 2026, filed 11 May 2026.